Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
T
4147
vs
T
Taiwan Weighted Index
Over the past 12 months, TaiMed Biologics Inc has underperformed Taiwan Weighted Index, delivering a return of -20% compared to Taiwan Weighted Index's +60% growth.
Stocks Performance
4147 vs Taiwan Weighted Index
Performance Gap
4147 vs Taiwan Weighted Index
Performance By Year
4147 vs Taiwan Weighted Index
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
TaiMed Biologics Inc
Glance View
TaiMed Biologics, Inc. engages in the new drug development for human immunodeficiency virus (HIV). The company is headquartered in Taipei City, Taipei. The company went IPO on 2010-06-28. The firm provides Trogarzo (TMB-355) for the treatment of Acquired Immune Deficiency Syndrome (AIDS). The firm's Trogarzo is a biweekly, long-acting monoclonal antibody drug primarily for multi-drug resistant patients with AIDS. The product is available in intravenous drip, intravenous push, and intramuscular dosage forms. The firm sells its products internationally.